Zinc is essential for the transcription function of Nrf2 in human renal tubule cells in vitro and mouse kidney in vivo under the diabetic condition

Journal of Cellular and Molecular Medicine

Volumn 18, Issue 5, 2014, Pages 895-906

  Li, Bing ^a,b,c   Cui, Wenpeng ^a,b   Tan, Yi ^b,d   Luo, Ping ^a   Chen, Qiang ^b   Zhang, Chi ^b,d   Qu, Wei ^e   Miao, Lining ^a   Cai, Lu ^b,d,f  

^a THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^b UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^c Jilin Province People's Hospital   (China)

^d WENZHOU MEDICAL UNIVERSITY   (China)

^e NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^f University of Louisville School of Medicine   (United States)

Author keywords

Akt phosphorylation; Diabetic nephropathy; Fyn; Nrf2; TPEN; Zinc chelation

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; GLUCOSE; PALMITIC ACID DERIVATIVE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE B; PROTEIN KINASE FYN; TRANSCRIPTION FACTOR NRF2; ZINC;

ANIMAL; BIOLOGICAL MODEL; CELL LINE; CELL NUCLEUS; DEFICIENCY; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; FIBROSIS; GENETIC TRANSCRIPTION; GENETICS; HUMAN; INFLAMMATION; KIDNEY TUBULE; METABOLISM; MOUSE; OXIDATIVE STRESS; PATHOLOGY; PROTEIN TRANSPORT; UPREGULATION;

ANIMALS; CELL LINE; CELL NUCLEUS; CONNECTIVE TISSUE GROWTH FACTOR; DIABETES MELLITUS, EXPERIMENTAL; FIBROSIS; GLUCOSE; HUMANS; INFLAMMATION; KIDNEY TUBULES; MICE; MODELS, BIOLOGICAL; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; PALMITATES; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-FYN; TRANSCRIPTION, GENETIC; UP-REGULATION; ZINC;

EID: 84900557344     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12239     Document Type: Article

References (53)

1. Jansen J, Karges W, Rink L. Zinc and diabetes-clinical links and molecular mechanisms. J Nutr Biochem. 2009; 20: 399-417.
2. Tomat AL, Costa Mde L, Arranz CT. Zinc restriction during different periods of life: influence in renal and cardiovascular diseases. Nutrition. 2011; 27: 392-8.
3. Yanagisawa H, Moridaira K, Wada O. Zinc deficiency further increases the enhanced expression of endothelin-1 in glomeruli of the obstructed kidney. Kidney Int. 2000; 58: 575-86.
4. Capdor J, Foster M, Petocz P, et al. Zinc and glycemic control: a meta-analysis of randomised placebo controlled supplementation trials in humans. J Trace Elem Med Biol. 2013; 27: 137-42.
5. Jayawardena R, Ranasinghe P, Galappatthy P, et al. Effects of zinc supplementation on diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr. 2012; 4: 13.
6. Soinio M, Marniemi J, Laakso M, et al. Serum zinc level and coronary heart disease events in patients with type 2 diabetes. Diabetes Care. 2007; 30: 523-8.
7. Fushimi H, Inoue T, Yamada Y, et al. Zinc deficiency exaggerates diabetic osteoporosis. Diabetes Res Clin Pract. 1993; 20: 191-6.
8. Zhao Y, Tan Y, Dai J, et al. Exacerbation of diabetes-induced testicular apoptosis by zinc deficiency is most likely associated with oxidative stress, p38 MAPK activation, and p53 activation in mice. Toxicol Lett. 2011; 200: 100-6.
9. Zhang C, Lu X, Tan Y, et al. Diabetes-induced hepatic pathogenic damage, inflammation, oxidative stress, and insulin resistance was exacerbated in zinc deficient mouse model. PLoS ONE. 2012; 7: e49257.
10. Wang J, Song Y, Elsherif L, et al. Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation. 2006; 113: 544-54.
11. Tang Y, Yang Q, Lu J, et al. Zinc supplementation partially prevents renal pathological changes in diabetic rats. J Nutr Biochem. 2010; 21: 237-46.
12. Karatug A, Kaptan E, Bolkent S, et al. Alterations in kidney tissue following zinc supplementation to STZ-induced diabetic rats. J Trace Elem Med Biol. 2013; 27: 52-7.
13. Ozcelik D, Naziroglu M, Tuncdemir M, et al. Zinc supplementation attenuates metallothionein and oxidative stress changes in kidney of streptozotocin-induced diabetic rats. Biol Trace Elem Res. 2012; 150: 342-9.
14. Apostolova MD, Choo KH, Michalska AE, et al. Analysis of the possible protective role of metallothionein in streptozotocin-induced diabetes using metallothionein-null mice. J Trace Elem Med Biol. 1997; 11: 1-7.
15. Cortese MM, Suschek CV, Wetzel W, et al. Zinc protects endothelial cells from hydrogen peroxide via Nrf2-dependent stimulation of glutathione biosynthesis. Free Radic Biol Med. 2008; 44: 2002-12.
16. Ha KN, Chen Y, Cai J, et al. Increased glutathione synthesis through an ARE-Nrf2-dependent pathway by zinc in the RPE: implication for protection against oxidative stress. Invest Ophthalmol Vis Sci. 2006; 47: 2709-15.
17. He X, Kan H, Cai L, et al. Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes. J Mol Cell Cardiol. 2009; 46: 47-58.
18. Tan Y, Ichikawa T, Li J, et al. Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo. Diabetes. 2011; 60: 625-33.
19. Suzuki M, Betsuyaku T, Ito Y, et al. Down-regulated NF-E2-related factor 2 in pulmonary macrophages of aged smokers and patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2008; 39: 673-82.
20. Kim HJ, Vaziri ND. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol. 2010; 298: F662-71.
21. Mehta AJ, Joshi PC, Fan X, et al. Zinc supplementation restores PU.1 and Nrf2 nuclear binding in alveolar macrophages and improves redox balance and bacterial clearance in the lungs of alcohol-fed rats. Alcohol Clin Exp Res. 2011; 35: 1519-28.
22. Pan HZ, Zhang L, Guo MY, et al. The oxidative stress status in diabetes mellitus and diabetic nephropathy. Acta Diabetol. 2010; 47: 71-6.
23. Yoh K, Hirayama A, Ishizaki K, et al. Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice. Genes Cells. 2008; 13: 1159-70.
24. Jiang T, Huang Z, Lin Y, et al. The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes. 2010; 59: 850-60.
25. Xue M, Qian Q, Adaikalakoteswari A, et al. Activation of NF-E2-related factor-2 reverses biochemical dysfunction of endothelial cells induced by hyperglycemia linked to vascular disease. Diabetes. 2008; 57: 2809-17.
26. Luo ZF, Qi W, Feng B, et al. Prevention of diabetic nephropathy in rats through enhanced renal antioxidative capacity by inhibition of the proteasome. Life Sci. 2011; 88: 512-20.
27. Zheng H, Whitman SA, Wu W, et al. Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes. 2011; 60: 3055-66.
28. Adler M, Dinterman RE, Wannemacher RW. Protection by the heavy metal chelator N, N, N', N'-tetrakis (2-pyridylmethyl)ethylenediamine (TPEN) against the lethal action of botulinum neurotoxin A and B. Toxicon. 1997; 35: 1089-100.
29. Kabu K, Yamasaki S, Kamimura D, et al. Zinc is required for Fc epsilon RI-mediated mast cell activation. J Immunol. 2006; 177: 1296-305.
30. Wang Y, Feng W, Xue W, et al. Inactivation of GSK-3beta by metallothionein prevents diabetes-related changes in cardiac energy metabolism, inflammation, nitrosative damage, and remodeling. Diabetes. 2009; 58: 1391-402.
31. Cai L, Chen S, Evans T, et al. Endothelin-1-mediated alteration of metallothionein and trace metals in the liver and kidneys of chronically diabetic rats. Int J Exp Diabetes Res. 2002; 3: 193-8.
32. Song Y, Li C, Cai L. Fluvastatin prevents nephropathy likely through suppression of connective tissue growth factor-mediated extracellular matrix accumulation. Exp Mol Pathol. 2004; 76: 66-75.
33. Zhong W, McClain CJ, Cave M, et al. The role of zinc deficiency in alcohol-induced intestinal barrier dysfunction. Am J Physiol Gastrointest Liver Physiol. 2010; 298: G625-33.
34. Rane MJ, Song Y, Jin S, et al. Interplay between Akt and p38 MAPK pathways in the regulation of renal tubular cell apoptosis associated with diabetic nephropathy. Am J Physiol Renal Physiol. 2010; 298: F49-61.
35. Negi G, Kumar A, Sharma SS. Nrf2 and NF-kappaB modulation by sulforaphane counteracts multiple manifestations of diabetic neuropathy in rats and high glucose-induced changes. Curr Neurovasc Res. 2011; 8: 294-304.
36. Cui W, Bai Y, Miao X, et al. Prevention of diabetic nephropathy by sulforaphane: possible role of nrf2 upregulation and activation. Oxid Med Cell Longev. 2012; 2012: 821936.
37. Tang X, Shay NF. Zinc has an insulin-like effect on glucose transport mediated by phosphoinositol-3-kinase and Akt in 3T3-L1 fibroblasts and adipocytes. J Nutr. 2001; 131: 1414-20.
38. Kaspar JW, Jaiswal AK. Tyrosine phosphorylation controls nuclear export of Fyn, allowing Nrf2 activation of cytoprotective gene expression. FASEB J. 2011; 25: 1076-87.
39. Jain AK, Jaiswal AK. GSK-3beta acts upstream of Fyn kinase in regulation of nuclear export and degradation of NF-E2 related factor 2. J Biol Chem. 2007; 282: 16502-10.
40. Zhou G, Li C, Cai L. Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor beta-independent pathway. Am J Pathol. 2004; 165: 2033-43.
41. McMahon M, Lamont DJ, Beattie KA, et al. Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals. Proc Natl Acad Sci USA. 2010; 107: 18838-43.
42. Omata Y, Salvador GA, Supasai S, et al. Decreased zinc availability affects glutathione metabolism in neuronal cells and in the developing brain. Toxicol Sci. 2013; 133: 90-100.
43. Koo JH, Lee WH, Lee CG, et al. Fyn inhibition by cycloalkane-fused 1, 2-dithiole-3-thiones enhances antioxidant capacity and protects mitochondria from oxidative injury. Mol Pharmacol. 2012; 82: 27-36.
44. Brandao-Neto J, Silva CA, Figueiredo NB, et al. Zinc kinetics in insulin-dependent diabetes mellitus patients. Biometals. 2000; 13: 141-5.
45. Kinlaw WB, Levine AS, Morley JE, et al. Abnormal zinc metabolism in type II diabetes mellitus. Am J Med. 1983; 75: 273-7.
46. Fischer Walker CL, Ezzati M, Black RE. Global and regional child mortality and burden of disease attributable to zinc deficiency. Eur J Clin Nutr. 2009; 63: 591-7.
47. Hambidge KM, Krebs NF. Zinc deficiency: a special challenge. J Nutr. 2007; 137: 1101-5.
48. Oh HM, Yoon JS. Glycemic control of type 2 diabetic patients after short-term zinc supplementation. Nutr Res Pract. 2008; 2: 283-8.
49. Kazi TG, Afridi HI, Kazi N, et al. Copper, chromium, manganese, iron, nickel, and zinc levels in biological samples of diabetes mellitus patients. Biol Trace Elem Res. 2008; 122: 1-18.
50. Basaki M, Saeb M, Nazifi S, et al. Zinc, copper, iron, and chromium concentrations in young patients with type 2 diabetes mellitus. Biol Trace Elem Res. 2012; 148: 161-4.
51. Jansen J, Rosenkranz E, Overbeck S, et al. Disturbed zinc homeostasis in diabetic patients by in vitro and in vivo analysis of insulinomimetic activity of zinc. J Nutr Biochem. 2012; 23: 1458-66.
52. Joshi PC, Mehta A, Jabber WS, et al. Zinc deficiency mediates alcohol-induced alveolar epithelial and macrophage dysfunction in rats. Am J Respir Cell Mol Biol. 2009; 41: 207-16.
53. Xue J, Wang S, Wu J, et al. Zinc at sub-cytotoxic concentrations induces heme oxygenase-1 expression in human cancer cells. Cell Physiol Biochem. 2013; 32: 100-10.